May 2016

Beyond PD-1/CTLA-4: Immunotherapy Combos Explore New Ground

June 28, 2016

Clinical Articles

A variety of dual immunotherapy combination regimens are currently under exploration that could build upon the success seen with the addition of the CTLA-4 inhibitor ipilimumab (Yervoy) to PD-1 blockade with nivolumab (Opdivo) for the treatment of patients with advanced melanoma.

Precision Medicine Key for Value-Based Care

June 29, 2016

Clinical Articles

Precision oncology should play a vital role in the shift toward value-based medicine by helping to deliver more effective therapies with more manageable pricing profiles, according to John L. Marshall, MD.

Evidence for Selective Internal Radiation Therapy Continues to Emerge for Liver Tumors

July 01, 2016

Clinical Articles

The treatment of colorectal cancer (CRC) has remained a significant clinical challenge, since over 50% of patients present with or develop liver metastases, which is a leading cause of death; however, a recent phase III study showed promise for selective internal radiation therapy (SIRT) in combination with standard chemotherapy as a first-line treatment.

NCCN Tweaks Breast Cancer Recommendations

July 05, 2016

Clinical Articles

A number of small changes that were specific to neoadjuvant and adjuvant therapies were made to the NCCN breast cancer guidelines, additionally, the recommended treatments for patients with ER-positive disease were also modified.

Introduction to the Society for Immunotherapy of Cancer

July 05, 2016

Clinical Articles

The Society for Immunotherapy of Cancer (SITC) is the world's leading member-driven organization dedicated to professionals working in the field of cancer immunotherapy. A 501(c)(3) non-profit organization, SITC was established in 1984 to advance the science, development, and application of tumor immunology and cancer immunotherapy. SITC aims to make cancer immunotherapy a standard of care and the word "cure" a reality.

Biomarkers, Subtyping Help Guide Neoadjuvant/Adjuvant Breast Cancer Treatment Decisions

July 08, 2016

Clinical Articles

For patients with early-stage invasive breast cancer and known estrogen receptor, progesterone receptor, and HER2 status, ASCO's February 2016 release of their evidence-based recommendations helped define appropriate use of biomarker assay results in guiding adjuvant treatment decisions.